Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving treatments for autoimmune and inflammatory diseases, announced that new translational data for its RIPK2 scaffolding inhibitor, OD-07656, will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, from October 25-30, 2024.
The activation of RIPK2 in innate immune cells is associated with various aspects of inflammatory bowel disease (IBD) pathogenesis, serving as a signal transducer and amplifier of cytokine production. This presentation will highlight the anti-inflammatory and anti-fibrotic effects of RIPK2 scaffolding inhibition, a proprietary gene signature related to RIPK2 activation, its role in resistance to standard therapies, and the enhanced effectiveness of combining RIPK2 inhibition with standard treatments.
“Odyssey’s presentation reflects our commitment to developing potentially transformative therapies for patients with inflammatory diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “At this year’s ACG, we will present new data supporting the potential of our RIPK2 candidate as both a standalone treatment and a complementary therapy to enhance patient responses and tackle treatment resistance. We are excited about the prospects of an innate immune-targeted approach for IBD patients and look forward to sharing these findings with researchers and patients.”
Poster Presentation
Title: Blocking RIPK2 Scaffolding Inhibits Downstream Signaling that Drives Inflammatory Bowel Disease
Poster Number: P4328
Presenting Author: Marta Wlodarska, PhD
Date: October 29, 2024 | 10:30 AM – 4:00 PM ET | Pennsylvania Convention Center, Exhibit Hall E
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the standard of care for patients with autoimmune and inflammatory diseases by developing targeted therapies. Founded in 2021, Odyssey leverages the expertise of its drug discovery team and a comprehensive suite of tools to create a portfolio of internally developed candidates aimed at achieving deep and lasting remission in patients facing unmet medical needs across various inflammatory conditions.
